Impact of chronic diuretic treatment on glucose homeostasis

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Buscemi, Silvio ^a   Nicolucci, Antonio ^b   Lucisano, Giuseppe ^b   Galvano, Fabio ^c   Grosso, Giuseppe ^c   Massenti, Fatima M ^a   Amodio, Emanuele ^a   Bonura, Alice ^a   Sprini, Delia ^a   Rini, Giovam B ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b DPT Farmacologia Clinica ed Epidemiologia   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Diuretics; Hypertension; Insulin resistance; Type 2 diabetes; Uric acid

Indexed keywords

FUROSEMIDE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; SPIRONOLACTONE; URIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIURETIC THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 84889982236     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-80     Document Type: Article

References (46)

1. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Diabetes in America Bethesda, US: National Institute of Health 2 1995
2. Diabetes mellitus and hypertension. Epstein M, Sowers JR, Hypertension 1992 19 403 418
3. Hypertension and mortality in diabetic and non-dibetic Finnish men. Aromaa A, Reunanen A, Pyorala K, J Hypertens 1984 2 205 207 (Pubitemid 15101091)
4. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation. Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K, Johansson L, Lind L, Hypertension 2008 52 1030 1037
5. A double-blind, placebo controlled, crossover trial comparing the effects of Amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, Brown MJ, Hypertension 2012 59 934 942
6. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Elliott WJ, Meyer PM, Lancet 2007 369 201 207 (Pubitemid 46111014)
7. Serum potassium is associated with prediabetes and newly diagnosed diabetes in hypertensive adults from the general population: the KORA F4-study. Meisinger C, Stockl D, Ruckert IM, Doring A, Thorand B, Heier M, Huth C, Belcredi P, Kowall B, Rathmann W, Diabetologia 2013 56 484 491
8. Diabetes in patients with hypertension receiving pharmacological treatment. Lundgren H, Bjorkman L, Keiding P, Lundmark S, Bengtsson C, BMJ 1988 297 1512 (Pubitemid 19007551)
9. Diabetes in hypertensive women: an effect of antihypertensive drugs or the hypertensive state per se ? Bengtsson C, Blohmé C, Lapidus L, Lundgren H, Diabet Med 1988 5 261 264
10. Influence of long-term, low dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G, Probstfield JL, Stamler J, Arch Intern Med 1998 158 741 751 (Pubitemid 28204659)
11. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, JAMA 2002 288 2981 2997
12. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, Coresh J, Arthritis Rheum 2012 64 121 129
13. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). Franse LV, Pahorb M, Di Baric M, Shorrd RI, Wand JY, Somesd GW, Applegatee WB, J Hypertens 2000 18 1149 1154
14. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Vijan S, Hayward RA, Ann Intern Med 2003 138 593 602
15. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Gu Q, Burt VL, Dillon CF, Yoon S, Circulation 2012 126 2105 2114
16. Treatment of hypertension in the prevention and management of ischemic heart disease-a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S, Circulation 2007 115 2761 2788 (Pubitemid 46842793)
17. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. Eur Heart J 2007 28 1462 1536
18. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ, J Am Coll Cardiol 2009 53s5 28 34
19. Low dose hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. Fujiwara W, Izawa H, Ukai G, Yokoi H, Mukaide D, Kinoshita K, Morimoto SI, Ishii J, Ozaki Y, Nomura M, Heart Vessels 2012 PMID 22447467
20. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, Diabetes Care 2006 29 2592 2597 (Pubitemid 44912184)
21. Angiotensin receptor blocker/diurectic combination preserves insulin responses in obese hypertensives. Sowers JR, Raij L, Jialal I, Egan BM, Ofili EO, Samuel R, Zappe DH, Purkayastha D, Deedwania PC, J Hypertens 2010 28 176 179
22. Willett W, Nutrition Epidemiology New York: Oxford University Press 2 1988
23. Association of dietary patterns with insulin resistance and clinically silent carotid atherosclerosis in apparently healthy people. Buscemi S, Nicolucci A, Mattina A, Rosafio G, Massenti FM, Lucisano G, Galvano F, Amodio E, Pellegrini E, Barile AM, Maniaci V, Grosso G, Verga S, Sprini D, Rini GB, Eur J Clin Nutr 2013 67 1284 1290
24. Diagnosis and classification of diabetes mellitus. American Diabetes Association, Diabetes Care 2013 36s1 67 74
25. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Friedewald WT, Clin Chem 1972 18 499 502
26. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG, Ann Intern Med 2004 21 929 937
27. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, Diabetologia 1985 28 412 419 (Pubitemid 15018832)
28. Thiazide diuretics in the treatment of hypertension: an update. Salvetti A, Ghiadoni L, J Am Soc Nephrol 2006 17s2 25 29
29. Thiazide diuretics, potassium, and the development of diabetes. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL, Hypertension 2006 48 219 224 (Pubitemid 44309815)
30. Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution. The Verona young Men atherosclerosis risk factors study. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, Travia D, Zenti MG, Branzi P, Santi L, Muggeo M, Int J Obes Relat Metab Disord 1996 20 975 980 (Pubitemid 26366450)
31. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. Zavaroni I, Mazza S, Fantuzzi M, Dall'Aglio E, Bonora E, Delsignore R, Passeri M, Reaven GM, J Intern Med 1993 234 25 30 (Pubitemid 23240554)
32. Hyperuricemia and insulin resistance. Vuorinen-Markkola H, Yki-Järvinen H, J Clin Endocrinol Metab 1994 78 25 29 (Pubitemid 24026741)
33. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. Facchini F, Ida Chen Y-D, Hollenbeck CB, Reaven GM, JAMA 1991 266 3008 3011
34. The kidney: an unwilling accomplice in syndrome X. Reaven GM, Am J Kidney Dis 1997 30 928 931 (Pubitemid 27524362)
35. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary artery risk development in young adults. Rathmann W, Funkhouser E, Dyer AR, Roseman JM, Ann Epidemiol 1998 8 250 261 (Pubitemid 28208943)
36. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M, Hypertension 2003 41 1183 1190 (Pubitemid 36706063)
37. Uric acid and cardiovascular risk. Feig DI, Kang DH, Johnson RJ, N Engl J Med 2008 359 1811 1821
38. The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Jaques BC, Ginsberg MH, Arthritis Rheum 1982 25 508 521 (Pubitemid 12115846)
39. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH, Peters AM, Haskard DO, Arthritis Rheum 1997 40 955 965 (Pubitemid 27200014)
40. Association of serum uric acid and cardiovascular disease in healthy adults. Kivity S, Kopel E, Maor E, Abu-BAchar F, Segev S, Sidi Y, Olchovsky D, Am J Cardiol 2013 111 1146 1151
41. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Alderman MH, Cohen H, Madhavan S, Kivlighn S, Hypertension 1999 34 144 150 (Pubitemid 29325733)
42. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, JAMA 2003 289 2560 2572 (Pubitemid 37430158)
43. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, Arch Intern Med 2005 165 1401 1409 (Pubitemid 40973423)
44. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Gress TW, Nieto J, Shahar E, Wofford MR, Brancati FL, N Engl J Med 2000 342 905 912 (Pubitemid 30177050)
45. Diagnostic value of glycated haemoglobin HbA (1c) for the early detection of diabetes in high-risk subjects. Kim KS, Kim SK, Lee YK, Park SW, Cho YW, Diabet Med 2008 25 997 1000
46. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, Wu P, Teng X, Dong Y, Zhou J, Xu H, Zheng J, Li S, Tao T, Hu Y, Jia Y, Acta Diabetol 2010 47 231 236